Company news
Enveric Biosciences, Inc. (NASDAQ:ENVB) news
Every Enveric Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
September 1, 2026
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
July 28, 2026
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
June 29, 2026
Enveric Biosciences Announces Participation in 2026 BIO International Convention
June 16, 2026
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
June 9, 2026
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
June 2, 2026
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
May 19, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
May 15, 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
May 13, 2026
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
May 5, 2026
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
April 28, 2026
Enveric Biosciences to Participate in a Panel Discussion at Needham’s Virtual Psychedelics Forum
April 21, 2026
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 17, 2026
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 16, 2026
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
March 31, 2026
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
March 27, 2026
Enveric Biosciences Announces Registration of Five Trademarks
March 18, 2026
Enveric Biosciences Announces Withdrawal of Petition Against Its Patent
February 25, 2026
Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data
February 19, 2026
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option
January 29, 2026
Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
January 28, 2026
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
January 28, 2026
Enveric Biosciences Announces Patent Issuance
December 29, 2025
Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
December 12, 2025
Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
December 11, 2025
Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
December 9, 2025
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During...
December 4, 2025
Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
November 26, 2025
Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results
November 14, 2025
Enveric Biosciences Announces Reverse Stock Split
October 23, 2025
Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance
October 16, 2025
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1...
October 15, 2025
Enveric Biosciences to Explore Digital Asset Treasury Opportunities
October 14, 2025
Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials
October 2, 2025
Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
September 18, 2025
Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds
September 17, 2025
Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Dru...
September 17, 2025
Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission
September 16, 2025
Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA
September 2, 2025
Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indic...
August 28, 2025
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results
August 14, 2025
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
July 23, 2025
Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)
July 15, 2025
Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
June 24, 2025
Enveric Biosciences Announces Participation in 2025 BIO International Convention
June 16, 2025
Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders
June 10, 2025
Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
June 3, 2025
Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003
May 28, 2025
Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease
May 20, 2025